ArticleTranslational vision science & technology2021
Evaluation of the Ultrastructural and In Vitro Flow Properties of the PRESERFLO MicroShunt.
Article in Translational vision science & technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 23 citations in OpenAlex.
- Incidence, risk factors, and outcomes of numerical hypotony and choroidal effusion following PRESERFLO MicroShunt implantation.Acta ophthalmologica · 2026Article
- Transconjunctival Compression Sutures for Postoperative Hypotony After PRESERFLO MicroShunt Revision: A Case Report.Cureus · 2026Article
- Comparative Outcomes of Standalone Xen63 Gel Stent and Preserflo Microshunt Implantation: A Multicenter Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Article
- In vitro flow properties of Preserflo Michroshunt with an intraluminal stent.Eye (London, England) · 2025Article
- PRESERFLO™ MicroShunt as a treatment option for highly increased intraocular pressure in primary open angle glaucoma and pseudoexfoliation glaucoma.Eye (London, England) · 2025Article
- Risk factors and protective strategies for hypotony following preserflo microshunt implantation.Scientific reports · 2025Article
- Update on Surgical Techniques Best Practices to Optimize Outcomes Following Gel Stent Implantation.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- The use of intraluminal PRESERFLO stenting in avoiding early postoperative hypotony.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
- Article
- Intermediate-term impact on corneal endothelial cells and efficacy of Preserflo MicroShunt implantation in patients with open-angle glaucoma - a prospective study over two years.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Observational
- Flow characterization and structural alterations in Ahmed glaucoma FP7 tubes after in-vitro aging in silicone oil.PloS one · 2024Article
- Exploring the Pressure Characteristics of the PRESERFLO MicroShunt in In Vitro Studies and Effects of Sclera on Device Performance.Journal of clinical medicine · 2023Article
- A simple surgical solution for the treatment of persistent postoperative hypotony after PRESERFLO MicroShunt implantation.Eye (London, England) · 2023Article
- Systematic Preserflo MicroShunt Intraluminal Stenting for Hypotony Prevention in Highly Myopic Patients: A Comparative Study.Journal of clinical medicine · 2023Article
- Bleb geometry and morphology after Preserflo Microshunt surgery: Risk factors for surgical failure.PloS one · 2023Article
- Anterior Segment-Optical Coherence Tomography Bleb Morphology Comparison in Minimally Invasive Glaucoma Surgery: XEN Gel Stent vs. PreserFlo MicroShunt.Diagnostics (Basel, Switzerland) · 2022Article
- PreserFloVision (Basel, Switzerland) · 2022Review
- Article
- Novel Dual-Device Strategy: Failed PRESERFLO MicroShunt Connected to an Ahmed ClearPath - Case Report.Case reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To measure the in vitro flow properties of the PRESERFLO implant for comparison with the theoretical resistance to flow. Methods: The PRESERFLO was designed to control the flow of aqueous humor according to the Hagen-Poiseuille (HP) equation. Scanning electron microscopy (SEM) was performed to analyze the ultrastructure, and flow measurements were carried out using a gravity-flow setup. Results: SEM images of the PRESERFLO showed luminal diameters of 67.73 × 65.95 µm and 63.66 × 70.54 µm. The total diameter was 337.2 µm, and the wall was 154 µm wide. The theoretical calculation of the resistance to flow (R) for an aqueous humor (AH) viscosity of 0.7185 centipoises (cP) was 1.3 mm Hg/(µL/min). Hence, assuming a constant AH flow of 2 µL/min, the pressure differential across the device (ΔP) was estimated to be 2.6 mm Hg. The gravity-flow experiment allowed us to measure the experimental resistance to flow, which was RE = 1.301 mm Hg/(µL/min), in agreement with the theoretical resistance to flow R given by the HP equation. Conclusions: The experimental and theoretical flow testing showed that the pressure drop across this device would not be large enough to avoid hypotony unless the resistance to outflow of the sub-Tenon space was sufficient to control the intraocular pressure in the early postoperative period. Translational Relevance: The fluid properties of glaucoma subconjunctival drainage devices determine their specific bleb-forming capacity and ability to avoid hypotony and therefore their safety and efficacy profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.